Bloomberg Reported Thursday Apple Raised iPhone and iPad Prices in Japan After Yen Selloff
https://www.bloomberg.com/news/articles/2022-07-01/apple-hikes-iphone-ipad-prices-in-japan-after-yen-tanks?sref=ZoyErlU1
3M to Sell Rights to Neoplast and Neobun Brands and Related Assets in Thailand and Certain other Southeast Asia Countries; Terms Not Disclosed
3M (NYSE: MMM) has entered into an agreement to sell its rights to the Neoplast™ and Neobun™ brands and related assets in Thailand and certain other Southeast Asia countries, including the manufacturing assets of its Ladlumkaew, Thailand, facility to Selic Corp Public Company Limited (Selic), a company focusing on bon
Credit Suisse Upgrades Coupang to Outperform, Lowers Price Target to $19
Credit Suisse analyst Soyun Shin upgrades Coupang (NYSE:CPNG) from Neutral to Outperform and lowers the price target from $28 to $19.
DA Davidson Initiates Coverage On Harley-Davidson with Neutral Rating, Announces Price Target of $35
DA Davidson analyst Brandon Rolle initiates coverage on Harley-Davidson (NYSE:HOG) with a Neutral rating and announces Price Target of $35.
Akerna Shares Dip 53%, Here’s 78 Biggest Movers From Yesterday
Gainers
Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.
B of A Securities Downgrades Duck Creek Technologies to Neutral, Announces $16 Price Target
B of A Securities analyst Brad Sills downgrades Duck Creek Technologies (NASDAQ:DCT) from Buy to Neutral and announces $16 price target.
Oxford Biomedica Signed New Three year Agreement with AstraZeneca
Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, today announces that it has signed a new three year Master Services & Development Agreement ("the Agreement") with AstraZeneca UK Ltd ("AstraZeneca") which would facilitate potential future manufacturing opportunities for the AstraZeneca COVID-19 vaccine.
EF Hutton Maintains Buy on AMMO, Lowers Price Target to $9
EF Hutton analyst Edward Reilly maintains AMMO (NASDAQ:POWW) with a Buy and lowers the price target from $11 to $9.
Keybanc Maintains Underweight on WestRock, Lowers Price Target to $36
Keybanc analyst Adam Josephson maintains WestRock (NYSE:WRK) with a Underweight and lowers the price target from $44 to $36.
eToro Said To Abandon SPAC Merger
Retail stock and cryptocurrency brokerage platform eToro is reportedly not going ahead with its planned blank-check merger.